Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.